Screening
Request a plain-language explanation of ECG screening, relevant laboratory review, clinical history, and medication or substance checks. Ask what findings would postpone or exclude participation.
Cancún, Mexico · due diligence
Vetting Checklist
A practical, evidence-driven way to evaluate ibogaine programs in Cancún: verify what can be documented, identify what remains uncertain, and pause when basic safety questions do not receive clear answers.
Safety before promises. Documentation before confidence.
01 / Begin with proof
Treat every claim as a document request.
Start with the physical operation, not its marketing language. Ask for the facility’s legal and regulatory status in Quintana Roo, its complete physical address, and the name of the entity responsible for operations. A location that cannot be independently identified makes it harder to assess licensing, emergency access, and accountability.
Verify
before confidence
Use the same standard for staffing. Ask who is on site during screening, administration, monitoring, overnight observation, and escalation. Request the credentials and role descriptions needed to distinguish medical oversight from non-clinical support. Ibogaine is associated with serious cardiac risk; the U.S. Food and Drug Administration’s discussion of QT prolongation illustrates why a program should be able to explain how it evaluates rhythm-related risk rather than relying on reassurance.
- Confirm the facility’s location and operational identity before treating any statement about licensing as verified.
- Ask who provides medical coverage at each stage and what credentials are relevant to the work described.
- Separate written evidence from informal assurances, testimonials, and broad safety language.
02 / Cardiac safeguards
Ask how monitoring works when something changes.
“Medical monitoring” is not a complete answer. Ask whether the program uses baseline ECG assessment, whether it reviews medication and drug interactions, when it repeats screening, whether continuous telemetry is used, and who reads or responds to findings. A useful comparison point is the cardiac safety guide’s question set, which focuses on the operational details behind a general safety claim.
Monitoring
Ask whether monitoring is continuous, what equipment is used, where it occurs, and which trained person is responsible for noticing and acting on a change.
Escalation
Ask for the written emergency plan, the hospital transfer process, and any documented arrangements that govern handoff when onsite resources are not enough.
Build a file, not a feeling.
A credible evaluation should leave a paper trail. Request a sample medical-records release, a de-identified example of the type of ECG strip or report used in screening, written standard operating procedures, informed-consent materials, exclusion criteria, medication-review steps, and an emergency escalation plan. A program does not need to disclose another person’s private information to explain its own process.
Review consent and exclusions carefully.
Informed consent should describe meaningful uncertainty, foreseeable risks, alternatives, limitations of the setting, and criteria that may rule someone out. The core idea of informed consent is not a signature alone; it is a decision made with relevant information and without pressure. Vague consent language or a refusal to discuss exclusion criteria should be treated as a reason to slow down.
Do not confuse therapeutic framing with verified clinical safeguards. Harm-reduction language can be appropriate, but it does not substitute for documented monitoring, staffing, escalation, or consent practices.
Look for claims that can be checked.
Ask how outcomes and adverse events are documented, whether follow-up is recorded, and how the program distinguishes a personal story from a tracked result. Broad claims of safety, cure, or suitability for everyone are not a substitute for verifiable records. For broader context on why drug-related risks can vary with dose, setting, co-occurring conditions, and interactions, consult the National Institute on Drug Abuse overview of drugs and the brain.
03 / Pause signals
Red flags are operational, not stylistic.
Presentation quality is not evidence of readiness. Focus on gaps that prevent meaningful verification: anonymous operators, no identifiable physical facility, no continuous cardiac monitoring, one-size-fits-all dosing language, unclear escalation procedures, or promises too broad to support. The broader Mexico program landscape can provide comparison context, but each location still requires its own documented review.
Identity gaps
Pause when the operator will not identify who runs the program, where it occurs, or who takes responsibility for clinical and emergency decisions.
Protocol gaps
Pause when screening, medication review, telemetry, dosing decisions, exclusions, or transfer planning are described only in general terms.
Evidence gaps
Pause when testimonials replace records, adverse events are not discussed, or outcome claims cannot be tied to a documented follow-up process.
04 / Compare carefully
Use third-party references without outsourcing judgment.
Look beyond a program’s own materials. Seek reputational references that are specific enough to check, ask what independent parties can confirm, and compare answers across settings. Background material on what ibogaine does may help frame questions, while a review of treatment-facility considerations can make operational differences easier to notice.
What should a program be willing to provide?
At minimum, it should be able to discuss records release, screening documentation, medication review, written protocols, emergency escalation, informed consent, and exclusions. Use a clinic dossier template to keep requests and answers in one comparable record.
What signals a need to pause?
Pause if the operator is anonymous, the physical location is unclear, clinical staffing cannot be explained, continuous cardiac monitoring is absent, dosing is presented as universal, or broad claims outrun the available documentation.
How should “experience” be weighed?
Experience is a claim to examine, not a replacement for safeguards. Materials discussing an ibogaine trip experience may describe expectations, but they do not establish the adequacy of screening, monitoring, or emergency preparation.
Why compare more than one setting?
Comparison makes missing details visible. If you are considering other jurisdictions, information about ibogaine options in Canada can widen the frame, while the questions themselves should remain consistent across locations.
Keep the checklist independent of the sales conversation.
Record what was requested, what was provided, who answered, and what remains unverified. This is due diligence, not a diagnosis or a recommendation. If the setting cannot support a careful review, uncertainty is the appropriate conclusion. For a wider view of the questions guiding this work, visit Coral Triage’s Cancún evaluation resource; its independent standards and mission explain the principles behind the checklist. For unrelated context on structured readiness and risk in high-intensity settings, the approach to ibogaine and martial arts discussions may offer a useful contrast in how preparation should be distinguished from bravado.
Open the clinic dossier template